1. Academic Validation
  2. SFRP1 modulates astrocyte-to-microglia crosstalk in acute and chronic neuroinflammation

SFRP1 modulates astrocyte-to-microglia crosstalk in acute and chronic neuroinflammation

  • EMBO Rep. 2021 Nov 4;22(11):e51696. doi: 10.15252/embr.202051696.
Javier Rueda-Carrasco 1 2 María Jesús Martin-Bermejo 1 2 Guadalupe Pereyra 1 2 María Inés Mateo 1 2 Aldo Borroto 1 Frederic Brosseron 3 4 Markus P Kummer 3 4 Stephanie Schwartz 3 4 José P López-Atalaya 5 Balbino Alarcon 1 Pilar Esteve 1 2 Michael T Heneka 3 4 Paola Bovolenta 1 2
Affiliations

Affiliations

  • 1 Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Madrid, Spain.
  • 2 CIBER de Enfermedades Raras (CIBERER), Madrid, Spain.
  • 3 Neurology, Universitätsklinikum Bonn, Bonn, Germany.
  • 4 German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • 5 Instituto de Neurociencias, CSIC-UMH, Sant Joan d'Alacant, Spain.
Abstract

Neuroinflammation is a common feature of many neurodegenerative diseases. It fosters a dysfunctional neuron-microglia-astrocyte crosstalk that, in turn, maintains microglial cells in a perniciously reactive state that often enhances neuronal damage. The molecular components that mediate this critical communication are not fully explored. Here, we show that secreted frizzled-related protein 1 (SFRP1), a multifunctional regulator of cell-to-cell communication, is part of the cellular crosstalk underlying neuroinflammation. In mouse models of acute and chronic neuroinflammation, SFRP1, largely astrocyte-derived, promotes and sustains microglial activation, and thus a chronic inflammatory state. SFRP1 promotes the upregulation of components of the hypoxia-induced factor-dependent inflammatory pathway and, to a lower extent, of those downstream of the nuclear factor-kappa B. We thus propose that SFRP1 acts as an astrocyte-to-microglia amplifier of neuroinflammation, representing a potential valuable therapeutic target for counteracting the harmful effect of chronic inflammation in several neurodegenerative diseases.

Keywords

Alzheimer's disease; HIF pathway; activated microglia; multiple sclerosis; reactive astrocytes.

Figures